eXmoor Pharma Strengthens Board with Appointment of Dr James Miskin as Non-Executive Director
Bristol, UK – 1 April, 2025 — eXmoor Pharma, a full-service Cell and Gene Therapy (CGT) CDMO, has appointed Dr James Miskin as Non-Executive Director.
James brings extensive experience in the cell and gene therapy sector, following a 23-year tenure at Oxford Biomedica. He oversaw delivery of the first-ever commercial batches of lentiviral vectors to manufacture the first FDA-approved CAR-T therapy, which has now been dosed in over 8,000 patients globally. James is widely recognised as a leader in CGT innovation, having supported the success of key programmes across the sector as it has matured into a multi-billion-dollar end market with dozens of regulatory approvals.
Commenting on his appointment, James said:
"I’m looking forward to supporting eXmoor as it continues to expand its GMP operations and help clients navigate the path to commercialisation. It’s an exciting time for the cell and gene therapy sector, and eXmoor has a key role to play."
Angela Osborne, CEO and founder of eXmoor Pharma, added:
"James’s appointment comes at a pivotal moment for eXmoor . His depth of experience in clinical and commercial manufacturing, combined with his strategic insight, makes him an invaluable addition to our board. I’m delighted to welcome him not just as a Non-Executive Director, but also as an advisor to our senior team, where his perspective will be instrumental as we scale our operations and support clients across the full CGT lifecycle."
James is also a founding director of the Biotechnology and Biological Sciences Research Council-funded ABViP programme, a collaborative training partnership with the University of Oxford and University College London, and continues to support various organisations as an independent consultant.
This appointment reinforces eXmoor Pharma’s commitment to providing expert-led, full-service support across translational consultancy, process development and GMP manufacturing. With consultancy embedded from early-phase strategy through to commercialisation, eXmoor ensures clients have the freedom and flexibility to develop breakthrough therapies without restriction.
About eXmoor Pharma
eXmoor Pharma is an integrated cell and gene therapy CDMO with consultancy expertise embedded at every stage, from early-phase strategy to GMP manufacturing and commercialisation.
Founded in 2004 and specialising in CGT since 2007, eXmoor helps organisations implement the right CMC strategy for their therapy.
Combining GMP manufacturing with embedded consultancy, eXmoor delivers full-service support across translational consulting, process and analytical development, facility design and clinical manufacturing. The company has completed over 560 projects for more than 170 clients globally.
eXmoor’s advanced therapies facility in Bristol, UK, supports Viral Vectors, Autologous and Allogeneic Cell Therapies, and RNA Technologies. Clients retain full IP control while benefiting from flexible, strategic partnerships that enable commercial success and long-term growth.
